← Back to StoryBreak

GLP-1 Vision-Loss Lawsuits Grow as Scientists Debate Whether Ozempic Causes NAION

Hundreds of patients have sued makers of Ozempic and related GLP-1 drugs, alleging they were not adequately warned about non-arteritic anterior ischemic optic neuropathy, a rare condition that can cause sudden vision loss. European regulators have recognized a very rare semaglutide risk, but U.S. studies remain divided over whether the drugs cause NAION.

Editorial illustration of anonymized health-discussion bubbles flowing into an AI data-analysis interface with molecular and injection-pen motifs
AI-generated image / StoryBreak

A federal litigation track involving Ozempic and other GLP-1 drugs is expanding around allegations that the medications can cause non-arteritic anterior ischemic optic neuropathy, or NAION — a rare eye condition that can produce sudden, permanent vision loss.

As of October 1, 2026, 247 cases were pending in the federal multidistrict litigation in the Eastern District of Pennsylvania, according to litigation-status reporting that cites Judicial Panel on Multidistrict Litigation records. The cases include allegations involving semaglutide products such as Ozempic and Wegovy, along with other GLP-1 medicines.

The lawsuits generally argue that manufacturers failed to adequately warn patients and doctors about a possible connection between the drugs and NAION. Those allegations have not been proved in court. The litigation is still in coordinated discovery, and no finding has established that Ozempic or another GLP-1 drug caused any individual plaintiff’s vision loss.

NAION is sometimes described as an “eye stroke.” It occurs when blood flow to the optic nerve is interrupted. Symptoms can include sudden, painless vision loss, often noticed after waking. Diabetes, high blood pressure, sleep apnea and other conditions can also raise the risk, making it difficult for researchers to determine whether a drug is responsible in a particular case.

The medical evidence is mixed. A 2026 systematic review and meta-analysis found an elevated association between semaglutide and NAION in some observational studies of people with Type 2 diabetes. But another 2026 analysis of randomized, placebo-controlled trials involving nearly 97,000 participants found fewer confirmed NAION cases among people receiving GLP-1 medicines than among those receiving placebo. The trial analysis concluded that its data did not suggest a relationship between treatment and NAION.

That difference matters. Observational studies can detect possible safety signals in large real-world populations, but patients taking a drug may differ from comparison groups in ways that are difficult to fully account for. Randomized trials are generally better at testing causation, but rare events may be missed when they occur only a few times across thousands of participants.

European regulators have taken a precautionary position. In June 2025, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee concluded that NAION should be listed as a “very rare” side effect of semaglutide medicines, meaning it may affect up to 1 in 10,000 people. The committee advised that patients experiencing sudden or rapidly worsening vision should contact a doctor promptly and said semaglutide should be stopped if NAION is confirmed.

That European action does not resolve the U.S. lawsuits or prove that semaglutide caused every reported injury. It does, however, provide an authoritative safety finding that plaintiffs are likely to point to as the American cases examine warning adequacy and general causation.

Novo Nordisk, the maker of Ozempic and Wegovy, has disputed the claims, pointing to later research that it says casts doubt on a causal connection. The company has said the lawsuits lack merit.

For patients, the practical issue is not whether to make an individual treatment decision based on a lawsuit headline. Anyone taking semaglutide who experiences sudden vision loss should seek urgent medical evaluation. Patients should not stop a prescribed medication without discussing the risks and alternatives with their clinician, unless an emergency-care professional directs them to do so.

The next major steps in the U.S. litigation are likely to involve expert evidence on whether GLP-1 drugs can cause NAION, how large any risk may be, and whether manufacturers provided adequate warnings. Those proceedings may narrow the scientific dispute before any representative cases proceed toward trial.

StoryBreak

Independent digital news and reporting, updated throughout the day.

This article was researched and drafted with AI assistance and reviewed as part of StoryBreak's editorial process before publication. Read our editorial standards.

Get the next stories

Email only, stored on StoryBreak. This form does not add a tracker. We'll email one confirmation link. Nothing is mailed until you open it.